RSS Amplifier

Vibe Bio · Aug 29, 2025

Vibe Bio Newsletter — August 2025

Read inOriginalenesdefrptjaittr
0
Sign in to vote or save

Vibe Bio · Vibe Bio

Here’s what’s driving headlines and conversations this month — from FDA decisions to AI breakthroughs.

Search & eval teams at rare disease biotechs are stretched thin as they track an expanding pipeline landscape. While core therapeutic areas like neuromuscular, particularly Duchenne muscular dystrophy (DMD), remain central, there is increasing interest in adjacent fields such as cardiac and the Central Nervous System (CNS), with a shift away from traditional genetic medicine toward more science-driven, modality-agnostic approaches.

Bandwidth challenges are acute: teams of just two to three people are managing surveillance of 400+ programs across multiple therapeutic areas. Prioritization tiers (shortlist, quarterly review, annual updates) help, but inflection points and new deals are easy to miss. It remains difficult to stay current and differentiate high-potential assets from the noise.

At one company we spoke to, there was strong interest in novel technology that can automate and streamline diligence, especially as AI platforms become more capable of analyzing public and confidential data, benchmarking programs, and surfacing risks. Tools that can reason like drug developers, provide citation-backed insights, and accommodate global (non-English) data are especially important, as they can enable more efficient triage and deeper coverage without additional headcount.

As one exec put it, “How do we find something that’s really new and exciting, not just a me-too drug? That takes looking deeper than a quick scan allows.”

If your organization faces similar challenges or has additional insights, please reach out. We’d love to hear from you.

With rising deal volume and shrinking timelines, BD&L teams face mounting pressure to evaluate more assets, faster—without compromising diligence. AI can help, but choosing the wrong solution risks missed opportunities.

Join us on September 24 at 1 PM ET for a practical, executive-level guide to evaluating AI for search, evaluation, and diligence. We’ll cover:

  • Why AI adoption is accelerating—and the cost of waiting to find a solution

  • How to spot the difference between generic tools and next-gen agentic AI

  • The must-have criteria for BD&L-ready AI: expertise, security, integration, and more

This 30-minute webinar will help you cut through the hype and evaluate AI solutions that are truly built for biopharma diligence.

Reserve your spot now to learn how to find the right path to AI-powered diligence in biopharma.

This month, we’ve been enjoying the last days of summer and getting some travel in!

Remie Yu visited Sri Lanka and took some stunning pics! She shared that the monkeys were cute from afar… but one snuck up behind her to steal a whole slice of watermelon instead of the scraps she was feeding them!

And Christina is on an adventure to Pakistan and Turkey!

Herbert stayed closer to home, but had a blast celebrating J’Ouvert in Boston! This vibrant street celebration marks the official start of Carnival, a cultural festival held annually in many Caribbean islands and worldwide.

We believe communities spark cures — let’s stay connected as we build the future together.

Tell us what else you’d like to see in future editions of the newsletter. We’d be happy to incorporate your suggestions!

Sincerely,

The Vibe Bio Team

#EveryCureforEveryCommunity

Subscribe to our newsletter

No posts

Read the original on vibebio.substack.com ↗

Comments

Nothing yet. Say the first thing.

    Sign in to join the conversation.